Filing summary
Important identity mismatch: The request identifies Jasper Therapeutics, Inc., but the supplied Form 10-K is for Amplitude Healthcare Acquisition Corporation (CIK/company identity should be verified before relying on this summary). Amplitude was a newly formed blank-check company seeking a business combination, not an operating therapeutics company.
Business context and reporting period
The audited fiscal-year filing covers August 13, 2019 (inception) through December 31, 2019; it does not provide a full-year or prior-year comparable operating period. Amplitude intended to target healthcare businesses, particularly life sciences and pharmaceutical services, but had not commenced operations or selected a target by year-end.
Financial metrics
| Metric | Reported amount |
|---|---|
| Revenue | None; no operating revenue had been generated. |
| Operating expenses / loss from operations | $136,304 |
| Trust-account interest income | $154,572 |
| Net income | $2,043, for the inception-to-year-end period |
| Cash outside trust | $1,212,755 at December 31, 2019 |
| Trust assets | $100,154,572 at December 31, 2019, invested in a U.S. Treasury money-market fund |
| Operating cash flow | $(367,473), used in operations |
| Debt and contractual obligations | No long-term debt reported. A $3.5 million deferred underwriting fee was payable only if a business combination closed; current liabilities were $111,364. |
| Equity/liquidity constraint | Net tangible assets had to remain at least $5,000,001 to complete a combination, subject to any higher transaction requirement. |
Margins are not meaningful because the company had no revenue. No comparable-period change can be assessed because the company was formed in 2019 and the filing provides no prior-year operating comparison. The IPO raised $100 million from 10 million units; a concurrent private placement raised $4 million. Transaction costs totaled $5,944,772.
Outlook, risks, contingencies and unusual items
- Management planned to complete a business combination by November 22, 2021. It reported no secured third-party financing and warned that additional funding might be unavailable or dilutive.
- If no combination closed by the deadline, public shares were to be redeemed from the trust, subject to creditor claims and applicable law; warrants would expire worthless. The stated trust value at year-end was approximately $10.02 per public share.
- Key SPAC risks include redemption-driven loss of deal funding, competition for targets, limited cash outside the trust, potential dilution from new securities and founder-share conversion adjustments, and conflicts arising from sponsor and management interests and other business obligations.
- The sponsor’s trust-protection indemnity is limited and its ability to pay was not verified. Creditor, bankruptcy or unenforceable-waiver claims could reduce public-share recoveries below $10 per share.
- COVID-19 was identified as a potential disruption to target searches, transaction execution and target businesses; the specific effect was not determinable, and the financial statements included no related adjustment.
- The auditor issued an unqualified opinion on the financial statements. Management said disclosure controls were effective at year-end; the filing did not include management’s internal-control assessment or an auditor attestation because of the newly public company transition period.
Most important facts for investors to verify
- Confirm the registrant and filing match the intended issuer: this document is for Amplitude Healthcare Acquisition Corporation, not Jasper Therapeutics, Inc.
- Verify trust-account balances, redemption terms, the November 22, 2021 deadline and any subsequent business-combination or liquidation filings.
- Review the deferred underwriting fee, sponsor indemnity and any claims or other obligations that could affect trust proceeds.
- Check subsequent disclosures for COVID-19 effects, financing, dilution, related-party arrangements and any transaction terms.